For the management of HER2-positive GC and GEJC, all guidelines recommend adding trastuzumab to first-line chemotherapy regimens, which commonly include cisplatin and a fluoropyrimidine [56, 58, 60]. Here, ERBB2 is linked to gastric cancer.